prikaz prve stranice dokumenta Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research
  Download
PDF 1.69 MB
Scientific paper - Original scientific paper
Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research
European Journal of Immunology, 49 (2018), 2; 228-241. https://doi.org/10.1002/eji.201847611
Berhani, Orit; Glasner, Ariella; Kahlon, Shira; Duev‐Cohen, Alexandra; Yamin, Rachel; Horwitz, Elad; Enk, Jonatan; Moshel, Ofra; Varvak, Alexandar; Porgador, Angel; Jonjić, Stipan; Mandelboim, Ofer

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Berhani, O., Glasner, A., Kahlon, S., Duev‐Cohen, A., Yamin, R., Horwitz, E. ... Mandelboim, O. (2018). Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research. European Journal of Immunology, 49. (2), 228-241. doi: 10.1002/eji.201847611

Berhani, Orit, et al. "Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research." European Journal of Immunology, vol. 49, no. 2, 2018, pp. 228-241. https://doi.org/10.1002/eji.201847611

Berhani, Orit, Ariella Glasner, Shira Kahlon, Alexandra Duev‐Cohen, Rachel Yamin, Elad Horwitz, Jonatan Enk, et al. "Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research." European Journal of Immunology 49, no. 2 (2018): 228-241. https://doi.org/10.1002/eji.201847611

Berhani, O., et al. (2018) 'Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research', European Journal of Immunology, 49(2), pp. 228-241. doi: 10.1002/eji.201847611

Berhani O, Glasner A, Kahlon S, Duev‐Cohen A, Yamin R, Horwitz E, and sur.. Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research. European Journal of Immunology [Internet]. 2018 December 17 [cited 2024 May 14];49(2):228-241. doi: 10.1002/eji.201847611

O. Berhani, et al., "Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research", European Journal of Immunology, vol. 49, no. 2, pp. 228-241, December 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:846941. [Accessed: 14 May 2024]

Metadata
Title (english)Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research
AuthorOrit Berhani
AuthorAriella Glasner
AuthorShira Kahlon
AuthorAlexandra Duev‐Cohen
AuthorRachel Yamin
AuthorElad Horwitz
AuthorJonatan Enk
AuthorOfra Moshel
AuthorAlexandar Varvak
AuthorAngel Porgador
AuthorStipan Jonjić
AuthorOfer Mandelboim
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Center for Proteomics)
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Histology and Embryology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
Natural killer (NK) cells are innate lymphocytes that efficiently eliminate cancerous and infected cells. NKp46 is an important NK activating receptor shown to participate in recognition and activation of NK cells against pathogens, tumor cells, virally infected cells, and self-cells in autoimmune conditions, including type I and II diabetes. However, some of the NKp46 ligands are unknown and therefore investigating human NKp46 activity and its critical role in NK cell biology is problematic. We developed a unique anti-human NKp46 monocloncal antibody, denoted hNKp46.02 (02). The 02 mAb can induce receptor internalization and degradation. By binding to a unique epitope on a particular domain of NKp46, 02 lead NKp46 to lysosomal degradation. This downregulation therefore enables the investigation of all NKp46 activities. Indeed, using the 02 mAb we determined NK cell targets which are critically dependent on NKp46 activity, including certain tumor cells lines and human pancreatic beta cells. Most importantly, we showed that a toxin-conjugated 02 inhibits the growth of NKp46-positive cells; thus, exemplifying the potential of 02 in becoming an immunotherapeutic drug to treat NKp46-dependent diseases, such as, type I diabetes and NK and T cell related malignancies.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleEuropean Journal of Immunology
Numberingvol. 49, no. 2, pp. 228-241
p-ISSN0014-2980
e-ISSN1521-4141
DOIhttps://doi.org/10.1002/eji.201847611
URN:NBNurn:nbn:hr:184:846941
Publication2018-12-17
Document URLhttps://onlinelibrary.wiley.com/doi/10.1002/eji.201847611
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2022-02-21 17:12:07